Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?

Mölken, Maureen P.M.H. Rutten-van; Oostenbrink, Jan B.; Tashkin, Donald P.; Burkhart, D; Monz, Brigitta U.

doi:10.1378/chest.130.4.1117

Cited by 184 publications

(166 citation statements)

References 31 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…In a review study, Pickard et al [19] report the same phenomenon for cancer patients, who showed lower VAS ratings than EQ-5D utilities across all reviewed cancer studies. For patients with diabetes or chronic obstructive pulmonary disease [20], similar findings have been described, with VAS ratings lower than utilities. VAS ratings higher than utilities have been reported for inflammatory bowel syndrome patients [17].…”

Section: Discussionsupporting

confidence: 74%

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

et al. 2014

View full text Add to dashboard Cite

BACKGROUND:The European Quality of Life-5 Dimensions (EQ-5D) instrument combines questionnaire responses into a single utility estimate using country-specific value sets. Countries without a national value set are advised to select one based on geographic proximity. In the absence of a Swiss value set, we used foreign value sets to gain insights into their appropriateness for use with Swiss cancer patients. METHODS: EQ-5D health states and visual analogue scale (VAS) ratings were collected in one German and three Swiss oncology trials. Utilities were calculated based on the United Kingdom (UK), German (GE), French (FR) and European Union (EU) value sets. Resulting differences and Pearson partial correlation coefficients with corresponding VAS ratings were assessed. RESULTS: In total, 202 Swiss and 154 German patients undergoing cancer treatment completed at least two EQ-5D forms. The mean difference between GE-based and FR-, UK-or EU-based utilities was significantly larger than the differences between the latter. The absolute mean difference between utilities and VAS ratings was highest for GE-based utilities, for Swiss ( Originally published at: Matter-Walstra, Klazien; Klingbiel, Dirk; Szucs, Thomas; Pestalozzi, Bernhard C; Schwenkglenks, Matthias (2014). Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied? Pharmacoeconomics, 32(6):591-599. DOI: https://doi.org/10.1007/s40273-014-0151-0

show abstract

Section: Discussionsupporting

confidence: 74%

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In addition, several studies involved multicountry data sets in which individual countries were not identified. 210,273 The majority of studies reported HSUVs based on the EQ-5D (73 studies 220 Ding et al 182 found patients with asthma-COPD overlap syndrome (ACOS) and asthma only to have the lowest HSUVs in comparison with COPD only (COPD, chronic bronchitis or emphysema) or controls (those without asthma, COPD, chronic bronchitis or emphysema). In contrast, Miravitlles et al…”

Section: Data Itemsmentioning

confidence: 99%

The health impacts of energy performance investments in low-income areas: a mixed-methods approach

et al. 2018

View full text Add to dashboard Cite

BackgroundCold homes and fuel poverty contribute to health inequalities in ways that could be addressed through energy efficiency interventions.ObjectivesTo determine the health and psychosocial impacts of energy performance investments in low-income areas, particularly hospital admissions for cardiorespiratory conditions, prevalence of respiratory symptoms and mental health status, hydrothermal conditions and household energy use, psychosocial outcomes, cost consequences to the health system and the cost utility of these investments.DesignA mixed-methods study comprising data linkage (25,908 individuals living in 4968 intervention homes), a field study with a controlled pre-/post-test design (intervention,n = 418; control,n = 418), a controlled multilevel interrupted time series analysis of internal hydrothermal conditions (intervention,n = 48; control,n = 40) and a health economic assessment.SettingLow-income areas across Wales.ParticipantsResidents who received energy efficiency measures through the intervention programme and matched control groups.Main outcome measuresPrimary outcomes – emergency hospital admissions for cardiorespiratory conditions, self-reported respiratory symptoms, mental health status, indoor air temperature and indoor relative humidity. Secondary outcomes – emergency hospital admissions for chronic obstructive pulmonary disease-related cardiorespiratory conditions, excess winter admissions, health-related quality of life, subjective well-being, self-reported fuel poverty, financial stress and difficulties, food security, social interaction, thermal satisfaction and self-reported housing conditions.MethodsAnonymously linked individual health records for emergency hospital admissions were analysed using mixed multilevel linear models. A quasi-experimental controlled field study used a multilevel repeated measures approach. Controlled multilevel interrupted time series analyses were conducted to estimate changes in internal hydrothermal conditions following the intervention. The economic evaluation comprised cost–consequence and cost–utility analyses.Data sourcesThe Patient Episode Database for Wales 2005–14, intervention records from 28 local authorities and housing associations, and scheme managers who delivered the programme.ResultsThe study found no evidence of changes in physical health. However, there were improvements in subjective well-being and a number of psychosocial outcomes. The household monitoring study found that the intervention raised indoor temperature and helped reduce energy use. No evidence was found of substantial increases in indoor humidity levels. The health economic assessment found no explicit cost reductions to the health service as a result of non-significant changes in emergency admissions for cardiorespiratory conditions.LimitationsThis was a non-randomised intervention study with household monitoring and field studies that relied on self-response. Data linkage focused on emergency admissions only.ConclusionAlthough there was no evidence that energy performance investments provide physical health benefits or reduce health service usage, there was evidence that they improve social and economic conditions that are conducive to better health and improved subjective well-being. The intervention has been successful in reducing energy use and improving the living conditions of households in low-income areas. The lack of association of emergency hospital admissions with energy performance investments means that we were unable to evidence cost saving to health-service providers.Future workOur research suggests the importance of incorporating evaluations with follow-up into intervention research from the start.FundingThe National Institute for Health Research Public Health Research programme.

show abstract

“…Rutten-van Molken et al 109 investigated the differences in COPD utility measured in 13 countries using data from a subset of 1235 trial patients (from 6000 participants) who completed a baseline European Quality of Life-5 Dimensions (EQ-5D) questionnaire 110 as part of a double-blind, placebo-RCT investigating whether dopropium reduces the rate of decline in forced expiratory volume. EQ-5D utility score was 0.76 at baseline; scores were split into six groups based on the severity of COPD (moderate, severe and very severe) and location (UK/USA); our model used an average of UK scores for all severities of COPD.…”

Section: Chronic Obstructive Pulmonary Disease Utilitiesmentioning

confidence: 99%

Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis.

Coleman

Agboola²,

Leonardi‐Bee³

et al. 2010

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA Relapse prevention in UK Stop Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch) and Current Contents / Clinical Medicine. NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in t...

show abstract

Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?

Cited by 184 publications

References 31 publications

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

The health impacts of energy performance investments in low-income areas: a mixed-methods approach

Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis.

Contact Info

Product

Resources

About